Bendicio, Kyle N.
HRN: 26-06-78 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/26/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/26/2024
11/01/2024
IV
35
Q24
PSNB
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes